Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 7 |
| List of Tables | 6 | 2 |
| List of Figures | 8 | 2 |
| Emerging Cancer Vaccines Market to 2017: Introduction | 10 | 2 |
| GBI Research Report Guidance | 10 | 2 |
| Emerging Cancer Vaccines Market to 2017: Cancer Vaccine Development | 12 | 6 |
| Different Approaches to Cancer Vaccine Development | 12 | 1 |
| Whole-Cell Cancer Vaccines | 12 | 1 |
| Overview | 12 | 1 |
| Case Study: Provenge, Dendreon Corporation | 12 | 1 |
| Antigen Vaccines | 12 | 1 |
| Overview | 12 | 1 |
| Case Study: GV1001, KAEL-Gemvax | 13 | 1 |
| DNA Vaccines | 13 | 1 |
| Overview | 13 | 1 |
| Case Study: VGX-3100, Inovio Pharmaceuticals | 13 | 1 |
| Vector-based Vaccines | 13 | 1 |
| Overview | 13 | 1 |
| Case Study: Prostvac, Bavarian Nordic | 13 | 1 |
| Dendritic Cell (DC) Vaccines | 14 | 1 |
| Overview | 14 | 1 |
| Case Study: Provenge, Dendreon Corporation | 14 | 1 |
| Idiotype Vaccines | 14 | 1 |
| Overview | 14 | 1 |
| Case Study: BiovaxID, BioVest International | 14 | 1 |
| Cancer Vaccines in Combination Therapy (Adjuvants) | 15 | 1 |
| Microbes | 15 | 1 |
| Overview | 15 | 1 |
| Case Study: BCG Vaccine for Prostate Cancer | 15 | 1 |
| Substances Produced by Bacteria | 15 | 1 |
| Overview | 15 | 1 |
| Case Study: Melacine for Melanoma | 16 | 1 |
| Biological Products Derived from Non-Microbial Organisms | 16 | 1 |
| Overview | 16 | 1 |
| Case Study: BiovaxID for NHL | 16 | 1 |
| Non-Biological Substances | 16 | 1 |
| Overview | 16 | 1 |
| Case Study: NY-ESO-1b Peptide and Montanide ISA-51 Vaccine for Advanced Epithelial Ovarian Cancer | 16 | 1 |
| Natural or Synthetic Cytokines | 17 | 1 |
| Overview | 17 | 1 |
| Case Study: OncoVEXGM-CSF for Metastatic Melanoma | 17 | 1 |
| Emerging Cancer Vaccines Market to 2017: Physical Delivery Methods | 18 | 3 |
| Introduction | 18 | 1 |
| Tattooing | 18 | 1 |
| Overview | 18 | 1 |
| Case Study: Peptide Vaccine Delivery by Tattooing and Subcutaneous Injection | 18 | 1 |
| Gene Gun | 19 | 1 |
| Overview | 19 | 1 |
| Case Study: pNGVL4a-Sig/E7(detox)/HSP70 DNA Vaccination by Gene Gun, Biojector, and Syringe | 19 | 1 |
| Ultrasound | 19 | 1 |
| Overview | 19 | 1 |
| Case Study: DNA-hsp65 Vaccine for Unresectable Squamous Cell Carcinoma of the Head and Neck | 19 | 1 |
| Electroporation | 20 | 1 |
| Overview | 20 | 1 |
| Case Study: VGX-3100 for CIN | 20 | 1 |
| Laser | 20 | 1 |
| Overview | 20 | 1 |
| Case Study: Femtosecond Laser Delivery | 20 | 1 |
| Emerging Cancer Vaccines Market to 2017: Non-Physical Delivery Methods | 21 | 4 |
| Biological Gene Delivery Systems (Viral Vectors) | 21 | 1 |
| Overview | 21 | 1 |
| Case Study: Prostvac for Advanced Prostate Cancer | 21 | 1 |
| Non-Biological Gene Delivery Systems (Non-Viral Vectors) | 21 | 1 |
| Cationic Lipids/Liposomes | 21 | 1 |
| Overview | 21 | 1 |
| Case Study: Stimuvax for Unresectable, stage III Non-Small Cell Lung Cancer (NSCLC) | 22 | 1 |
| Polysaccharides and Cationic Polymers | 22 | 1 |
| Overview | 22 | 1 |
| Case Study: Herceptin-Conjugated Gemcitabine-Loaded Chitosan NPs for Pancreatic Cancer | 22 | 1 |
| Micro/Nano-particles | 22 | 1 |
| Overview | 22 | 1 |
| Case Study: Paclitaxel-Loaded PLGA NPs with Wheat Germ Agglutinin (WGA) | 23 | 1 |
| Cationic Peptides/CPP | 23 | 1 |
| Overview | 23 | 1 |
| Case Study: TAT-PEG-PEI Conjugate for Lung Cancer | 23 | 1 |
| Virus-Like Particles (VLPs) as an Efficient Delivery System | 23 | 1 |
| Overview | 23 | 1 |
| Case Study: V503 for Cervical Cancer | 23 | 1 |
| Delivery Systems in DC Vaccines | 24 | 1 |
| Delivery Systems in Protein/Peptide Vaccines | 24 | 1 |
| Mucosal Delivery System | 24 | 1 |
| Overview | 24 | 1 |
| Case Study: L. plantarum Expressing Oncofetal Antigen (OFA) for Mucosal Cancer Vaccine Delivery | 24 | 1 |
| Emerging Cancer Vaccines Market to 2017: Market Overview | 25 | 6 |
| Introduction | 25 | 1 |
| Revenue | 25 | 2 |
| Annual Cost of Vaccination | 27 | 1 |
| Target Population | 28 | 1 |
| Coverage Population | 28 | 1 |
| Unmet Needs | 29 | 1 |
| Drivers and Restraints | 29 | 1 |
| Drivers | 29 | 1 |
| Restraints | 29 | 2 |
| Emerging Cancer Vaccines Market to 2017: Therapeutic Landscape | 31 | 27 |
| Cervical Cancer Vaccines Market | 31 | 1 |
| Introduction | 31 | 1 |
| Unmet Needs | 31 | 1 |
| Revenue | 32 | 1 |
| Annual Cost of Vaccination | 33 | 1 |
| Target Population | 34 | 1 |
| Coverage Population | 34 | 2 |
| Geographical Segmentation | 36 | 1 |
| Drivers and Restraints for the Cervical Cancer Vaccines Market | 37 | 1 |
| Drivers | 37 | 1 |
| Restraints | 37 | 1 |
| Prostate Cancer Vaccine Market | 37 | 1 |
| Introduction | 37 | 1 |
| Unmet Needs | 37 | 1 |
| Revenue | 38 | 1 |
| Annual Cost of Vaccination | 39 | 1 |
| Target Population | 40 | 1 |
| Coverage Population | 40 | 1 |
| Geographical Segmentation | 41 | 1 |
| Drivers and Restraints for the Prostate Cancer Vaccines Market | 42 | 1 |
| Drivers | 42 | 1 |
| Restraints | 42 | 1 |
| Lung Cancer Vaccines Market | 42 | 1 |
| Introduction | 42 | 1 |
| Unmet Needs | 42 | 1 |
| Revenue | 43 | 1 |
| Annual Cost of Vaccination | 44 | 1 |
| Target Population | 45 | 1 |
| Coverage Population | 45 | 1 |
| Geographical Segmentation | 46 | 1 |
| Drivers and Restraints for the Lung Cancer Vaccines Market | 47 | 1 |
| Drivers | 47 | 1 |
| Restraints | 47 | 1 |
| Pancreatic Cancer Vaccines Market | 47 | 1 |
| Introduction | 47 | 1 |
| Unmet Needs | 47 | 1 |
| Revenue | 48 | 1 |
| Annual Cost of Vaccination | 49 | 1 |
| Target Population | 50 | 1 |
| Coverage Population | 50 | 1 |
| Geographical Segmentation | 51 | 1 |
| Drivers and Restraints for the Pancreatic Cancer Vaccines Market | 52 | 1 |
| Drivers | 52 | 1 |
| Restraints | 52 | 1 |
| Melanoma Vaccines Market | 52 | 1 |
| Introduction | 52 | 1 |
| Unmet Needs | 52 | 1 |
| Revenue | 53 | 1 |
| Annual Cost of Vaccination | 54 | 1 |
| Target Population | 55 | 1 |
| Coverage Population | 55 | 1 |
| Geographical Segmentation | 56 | 1 |
| Drivers and Restraints for the Melanoma Vaccines Market | 57 | 1 |
| Drivers | 57 | 1 |
| Restraints | 57 | 1 |
| Emerging Cancer Vaccines Market to 2017: Geographical Landscape | 58 | 12 |
| The US | 58 | 1 |
| Revenue | 58 | 2 |
| Annual Cost of Vaccination | 60 | 1 |
| Target Population | 61 | 1 |
| Coverage Population | 61 | 2 |
| Top Five Countries in Europe | 63 | 1 |
| Revenue | 63 | 1 |
| Annual Cost of Vaccination | 64 | 1 |
| Target Population | 65 | 1 |
| Coverage Population | 65 | 2 |
| Japan | 67 | 1 |
| Revenue | 67 | 1 |
| Annual Cost of Vaccination | 68 | 1 |
| Target Population | 69 | 1 |
| Coverage Population | 69 | 1 |
| Emerging Cancer Vaccines Market to 2017: Pipeline Analysis | 70 | 40 |
| Introduction | 70 | 2 |
| Research and Development Pipeline Prostate Cancer Vaccines | 72 | 6 |
| Research and Development Pipeline Lung Cancer Vaccines | 78 | 6 |
| Research and Development Pipeline Pancreatic Cancer Vaccines | 84 | 5 |
| Research and Development Pipeline Melanoma Vaccines | 89 | 13 |
| Research and Development Pipeline Cervical Cancer Vaccines | 102 | 3 |
| R&D Trends | 105 | 1 |
| Profiles of Promising Drugs in the Emerging Cancer Vaccines Market to 2017 | 105 | 1 |
| Stimuvax | 105 | 1 |
| Overview | 105 | 1 |
| Efficacy | 105 | 1 |
| Safety | 105 | 1 |
| Clinical Study Details | 105 | 1 |
| OncoVEXGM-CSF | 106 | 1 |
| Overview | 106 | 1 |
| Efficacy | 106 | 1 |
| Safety | 106 | 1 |
| Clinical Study Details | 106 | 1 |
| V503 | 106 | 1 |
| Overview | 106 | 1 |
| Efficacy | 106 | 1 |
| Safety | 106 | 1 |
| Clinical Study Details | 107 | 1 |
| GV1001 | 107 | 1 |
| Overview | 107 | 1 |
| Efficacy | 107 | 1 |
| Safety | 107 | 1 |
| Clinical Study Details | 107 | 1 |
| Lucanix | 108 | 1 |
| Overview | 108 | 1 |
| Efficacy | 108 | 1 |
| Safety | 108 | 1 |
| Clinical Study Details | 108 | 1 |
| TG4010 | 108 | 1 |
| Overview | 108 | 1 |
| Efficacy | 109 | 1 |
| Safety | 109 | 1 |
| Clinical Study Details | 109 | 1 |
| Emerging Cancer Vaccines Market to 2017: Competitive Landscape | 110 | 11 |
| Marketed Cancer Vaccines | 110 | 1 |
| Gardasil | 110 | 1 |
| Overview | 110 | 1 |
| Efficacy | 110 | 1 |
| Safety | 110 | 1 |
| Clinical Study Details | 110 | 1 |
| Cervarix | 110 | 1 |
| Overview | 110 | 1 |
| Efficacy | 110 | 1 |
| Safety | 111 | 1 |
| Clinical Study Details | 111 | 1 |
| Provenge | 111 | 1 |
| Overview | 111 | 1 |
| Efficacy | 111 | 1 |
| Safety | 111 | 1 |
| Clinical Study Details | 111 | 1 |
| Market Share Analysis | 112 | 1 |
| Competitive Profiling | 113 | 1 |
| Merck &Co., Inc. | 113 | 1 |
| Business Description | 113 | 1 |
| Product Portfolio | 113 | 1 |
| Pipeline Portfolio | 113 | 1 |
| SWOT Analysis | 114 | 1 |
| Merck Serono | 115 | 1 |
| Business Description | 115 | 1 |
| Pipeline Portfolio | 115 | 1 |
| SWOT Analysis | 115 | 1 |
| Amgen | 116 | 1 |
| Business Description | 116 | 1 |
| Pipeline Portfolio | 116 | 1 |
| SWOT Analysis | 116 | 1 |
| GlaxoSmithKline | 117 | 1 |
| Business Description | 117 | 1 |
| Product Portfolio | 117 | 1 |
| Pipeline Portfolio | 117 | 1 |
| SWOT Analysis | 118 | 1 |
| Dendreon | 119 | 1 |
| Business Description | 119 | 1 |
| Product Portfolio | 119 | 1 |
| Pipeline Portfolio | 119 | 1 |
| SWOT Analysis | 120 | 1 |
| KAEL-Gemvax | 120 | 1 |
| Business Description | 120 | 1 |
| Pipeline Portfolio | 120 | 1 |
| Emerging Cancer Vaccines Market to 2017: Strategic Consolidations | 121 | 24 |